View ValuationOxurion 将来の成長Future 基準チェック /06現在、 Oxurionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 06+ 1 more updateOxurion NV to Report Fiscal Year 2026 Results on Apr 02, 2027Oxurion NV announced that they will report fiscal year 2026 results on Apr 02, 2027お知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.6m). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€515k revenue, or US$547k). Market cap is less than US$10m (€575.4k market cap, or US$611.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Apr 06Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024Oxurion NV announced that they will report fiscal year 2023 results on Apr 15, 2024お知らせ • Jan 25Oxurion NV, Annual General Meeting, May 07, 2024Oxurion NV, Annual General Meeting, May 07, 2024, at 14:00 Central European Standard Time.お知らせ • Dec 30+ 2 more updatesOxurion Announces CEO ChangesOxurion NV announced it has avoided bankruptcy by entering into a binding letter of intent (LOI) with Atlas Special Opportunities LLC (Atlas) and an addendum to the existing subscription agreement for convertible bonds with Atlas. The Company appointed Pascal Ghoson as the new acting CEO/CFO, who is a former M&A specialist at Rothschild bank and CFO of various listed companies on Euronext. Tom Graney have stepped down from the Board as a condition of the LOI.お知らせ • Nov 20Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaOxurion NV announced that topline data in its KALAHARI Phase 2, Part B clinical trial for Diabetic macular edema (DME) (KALAHARI trial) did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as the comparator, the anti-VEGF therapy aflibercept, at Month 3 (the primary endpoint). The mean change in best corrected visual acuity (BCVA) from baseline at Month 3 was -0.2 letters for theTHR-149 arm and +3.5 letters for the aflibercept arm. The results confirmed that THR-149 was safe and well tolerated. The KALAHARI trial is the only ongoing trial sponsored by Oxurion. In light of these results and the Company's low cash position, the Company has therefore decided to take the necessary steps to file for bankruptcy. Oxurion's investigators over-enrolled the trial with a total of 112 patients, for whom the current standard of care is suboptimal in treating their DME, reflecting the strong interest of both investigators and patients. The KALAHari trial evaluated Oxurion's novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy. The continuation of the trial followed the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that it would not be futile for the KALAHARI trial to continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at Month 3 and followed encouraging data from the Part A dose- selection part of the KALAHARI trial.Board Change • Nov 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)First half 2023 results: €0.02 loss per share (improved from €0.32 loss in 1H 2022). Net loss: €10.6m (loss narrowed 27% from 1H 2022).Board Change • Sep 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 24Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023Oxurion NV announced that they will report first half, 2023 results on Sep 29, 2023お知らせ • May 26Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular EdemaOxurion NV announced that it has reached its enrollment target of 108 patients randomized in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial). As of Oxurion’s investigators have successfully enrolled the 108 patients planned for this trial. Given the high level of interest from both investigators and patients, additional patients are still likely to be included in the trial, which would mean the trial will be over-enrolled. As it has now reached its enrollment target, Oxurion confirms its previous guidance that it anticipates reporting top-line data from the KALAHARI trial in the fourth quarter of 2023. The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy, the current standard of care. This milestone follows the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that the KALAHARI trial should continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at the three-month time point. Approximately 22 million people worldwide have DME currently, with prevalence increasing due to the growing global diabetic epidemic. DME is the leading cause of vision loss in working-age people, and the market for treatments is currently estimated at +$5 billion. People who suffer from DME have leaking vessels in the back of the eye, leading to a thickening of the retina that causes vision problems such as blurriness in the center of vision, the appearance of dark spots or patches in the field of vision, and colors to look dull. These symptoms may affect the ability to read, write, drive, and recognize faces – presenting a significant patient and caregiver burden.Board Change • May 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 21Oxurion NV, Annual General Meeting, May 02, 2023Oxurion NV, Annual General Meeting, May 02, 2023.Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: €0.77 loss per share (down from €0.73 loss in FY 2020). Net loss: €29.2m (loss widened 4.1% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 1 Revenue exceeded analyst estimates by 147%. Over the next year, revenue is expected to shrink by 100% compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 20Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)Full year 2020 results: Net loss: €28.0m (loss narrowed 46% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 28New 90-day high: €2.92The company is up 19% from its price of €2.45 on 28 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: €2.35The company is down 15% from its price of €2.78 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.Is New 90 Day High Low • Oct 01New 90-day low: €2.40The company is down 20% from its price of €3.02 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total losses of €31.6m, with losses narrowing by 44% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Oxurion は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:TG40 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251-4-2-2N/A9/30/20250-1-2-2N/A6/30/202502-1-1N/A3/31/202501-2-2N/A12/31/202400-2-2N/A9/30/20240-6-3-3N/A6/30/20240-11-5-5N/A3/31/20240-15-7-7N/A12/31/20230-19-10-10N/A9/30/20230-23-11-11N/A6/30/20231-28-12-12N/A3/31/20231-30-16-16N/A12/31/20221-32-19-19N/A9/30/20221-30-23-23N/A6/30/20221-28-27-27N/A3/31/20221-28-27-27N/A12/31/20211-29-27-27N/A9/30/20211-30-27-27N/A6/30/20211-31-27-27N/A3/31/20212-29-27-27N/A12/31/20202-28-27-27N/A9/30/20203-30-28-28N/A6/30/20203-32-29-29N/A3/31/20204-42-30-30N/A12/31/20194-52-32-31N/A9/30/20194-54N/A-28N/A6/30/20193-57N/A-24N/A3/31/20194-48N/A-27N/A12/31/20185-38N/A-31N/A9/30/20186-8N/A-7N/A6/30/2018723N/A16N/A3/31/2018623N/A21N/A12/31/2017623N/A26N/A9/30/20176-19N/A0N/A6/30/20176-61N/A-27N/A3/31/20176-60N/A-23N/A12/31/20167-60N/A-20N/A9/30/20168-47N/A-20N/A6/30/20169-34N/A-21N/A3/31/201610-36N/A-24N/A12/31/201511-38N/A-28N/A9/30/201512-42N/A-33N/A6/30/201513-46N/A-39N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TG40の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: TG40の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: TG40の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: TG40の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: TG40の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TG40の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 00:59終値2026/06/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oxurion NV 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Roderick VerhelstDegroof PetercamDivya HarikeshGoldman SachsSteven ChesneyGoldman Sachs7 その他のアナリストを表示
お知らせ • Jun 06+ 1 more updateOxurion NV to Report Fiscal Year 2026 Results on Apr 02, 2027Oxurion NV announced that they will report fiscal year 2026 results on Apr 02, 2027
お知らせ • May 06Oxurion NV, Annual General Meeting, Jun 01, 2026Oxurion NV, Annual General Meeting, Jun 01, 2026, at 14:00 Romance Standard Time.
お知らせ • Nov 10Oxurion NV to Report Fiscal Year 2025 Results on Apr 03, 2026Oxurion NV announced that they will report fiscal year 2025 results on Apr 03, 2026
お知らせ • Jul 23Oxurion NV announced that it expects to receive €10 million in funding from Atlas Special Opportunities LLCOxurion NV entered into a term sheet agreement for a private placement to issue 6% convertible bonds for the proceeds of €10 million on July 22, 2025. The transaction involves participation of Atlas Special Opportunities LLC as returning investor. The bonds matures on 12 months from issuance and bears 6% interest. The expected closing of transaction is end of August 2025 and transaction will happen in 10 tranches.
お知らせ • Apr 07Oxurion NV, Annual General Meeting, May 13, 2025Oxurion NV, Annual General Meeting, May 13, 2025.
Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Net loss: €3.03m (loss narrowed 72% from 1H 2023).
Reported Earnings • Apr 17Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)Full year 2023 results: €0.01 loss per share (improved from €0.37 loss in FY 2022). Net loss: €19.0m (loss narrowed 40% from FY 2022).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.6m). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€515k revenue, or US$547k). Market cap is less than US$10m (€575.4k market cap, or US$611.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Apr 06Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024Oxurion NV announced that they will report fiscal year 2023 results on Apr 15, 2024
お知らせ • Jan 25Oxurion NV, Annual General Meeting, May 07, 2024Oxurion NV, Annual General Meeting, May 07, 2024, at 14:00 Central European Standard Time.
お知らせ • Dec 30+ 2 more updatesOxurion Announces CEO ChangesOxurion NV announced it has avoided bankruptcy by entering into a binding letter of intent (LOI) with Atlas Special Opportunities LLC (Atlas) and an addendum to the existing subscription agreement for convertible bonds with Atlas. The Company appointed Pascal Ghoson as the new acting CEO/CFO, who is a former M&A specialist at Rothschild bank and CFO of various listed companies on Euronext. Tom Graney have stepped down from the Board as a condition of the LOI.
お知らせ • Nov 20Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaOxurion NV announced that topline data in its KALAHARI Phase 2, Part B clinical trial for Diabetic macular edema (DME) (KALAHARI trial) did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as the comparator, the anti-VEGF therapy aflibercept, at Month 3 (the primary endpoint). The mean change in best corrected visual acuity (BCVA) from baseline at Month 3 was -0.2 letters for theTHR-149 arm and +3.5 letters for the aflibercept arm. The results confirmed that THR-149 was safe and well tolerated. The KALAHARI trial is the only ongoing trial sponsored by Oxurion. In light of these results and the Company's low cash position, the Company has therefore decided to take the necessary steps to file for bankruptcy. Oxurion's investigators over-enrolled the trial with a total of 112 patients, for whom the current standard of care is suboptimal in treating their DME, reflecting the strong interest of both investigators and patients. The KALAHari trial evaluated Oxurion's novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy. The continuation of the trial followed the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that it would not be futile for the KALAHARI trial to continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at Month 3 and followed encouraging data from the Part A dose- selection part of the KALAHARI trial.
Board Change • Nov 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)First half 2023 results: €0.02 loss per share (improved from €0.32 loss in 1H 2022). Net loss: €10.6m (loss narrowed 27% from 1H 2022).
Board Change • Sep 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 24Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023Oxurion NV announced that they will report first half, 2023 results on Sep 29, 2023
お知らせ • May 26Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular EdemaOxurion NV announced that it has reached its enrollment target of 108 patients randomized in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial). As of Oxurion’s investigators have successfully enrolled the 108 patients planned for this trial. Given the high level of interest from both investigators and patients, additional patients are still likely to be included in the trial, which would mean the trial will be over-enrolled. As it has now reached its enrollment target, Oxurion confirms its previous guidance that it anticipates reporting top-line data from the KALAHARI trial in the fourth quarter of 2023. The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy, the current standard of care. This milestone follows the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that the KALAHARI trial should continue based on the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at the three-month time point. Approximately 22 million people worldwide have DME currently, with prevalence increasing due to the growing global diabetic epidemic. DME is the leading cause of vision loss in working-age people, and the market for treatments is currently estimated at +$5 billion. People who suffer from DME have leaking vessels in the back of the eye, leading to a thickening of the retina that causes vision problems such as blurriness in the center of vision, the appearance of dark spots or patches in the field of vision, and colors to look dull. These symptoms may affect the ability to read, write, drive, and recognize faces – presenting a significant patient and caregiver burden.
Board Change • May 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Non-Executive Director Thomas Clay is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 21Oxurion NV, Annual General Meeting, May 02, 2023Oxurion NV, Annual General Meeting, May 02, 2023.
Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: €0.77 loss per share (down from €0.73 loss in FY 2020). Net loss: €29.2m (loss widened 4.1% from FY 2020). Products in clinical trials Phase I: 1 Phase II: 1 Revenue exceeded analyst estimates by 147%. Over the next year, revenue is expected to shrink by 100% compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 20Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)Full year 2020 results: Net loss: €28.0m (loss narrowed 46% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 28New 90-day high: €2.92The company is up 19% from its price of €2.45 on 28 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: €2.35The company is down 15% from its price of €2.78 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.
Is New 90 Day High Low • Oct 01New 90-day low: €2.40The company is down 20% from its price of €3.02 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total losses of €31.6m, with losses narrowing by 44% from the prior year.